IQUIMEFA   05518
INSTITUTO QUIMICA Y METABOLISMO DEL FARMACO
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
C-type natriuretic peptide chronic administration: beneficial effects on cardiac fibrosis and inflammatory state in a hypertension model
Autor/es:
PRENTKI, ESTEFANÍA; CANIFFI, CAROLINA; SUEIRO, LAURA; BOUCHET, GONZALO; REYES, ANA; TOBLLI, JORGE; ARRANZ, CRISTINA; COSTA, MARÍA DE LOS ÁNGELES
Lugar:
Foz de Iguazú
Reunión:
Congreso; 1st PanAmerican Congress of Physiological Sciences; 2014
Institución organizadora:
American Physiological Society
Resumen:
Aim: evaluate the effects of C-type Natriuretic Peptide (CNP) chronic treatment on cardiac fibrosis and its inflammatory state in spontaneously hypertensive rats (SHR) and Wistar normotensive ones (W). Methodology: 12-week-old male SHR and W were infused with CNP (0, 75 µg/hr) or saline (S) (osmotic pumps, 14 days). Systolic blood pressure (SBP, mmHg) was recorded by tail-cuff method. Finalizing the treatment, animals were decapitated and the left ventricle (LV) was extracted to determine: left ventricle mass index (LVMI, g LV/mm tibia longitude), fibrosis (Picrosirius-Red, %fibrosis) and inflammatory state (IL-6 and TNF-α immunohistochemistry, stain %/mm2). Statistics: Two way ANOVA, Bonferroni post-test. Results: SBP W: S=118±2, CNP=122±3; SHR: S= 175±3*, CNP= 159±5#. LVMI W: S=0,023±0,002, CNP=0,024±0,001; SHR: S=0,032±0,001*, CNP=0,029±0,001. Fibrosis W: S=1,54±0,53, CNP=1,78±0,17; SHR: S=6,81±0,40*, CNP=3,27±0,67#. IL- 6 W: S=1,8±1,0, CNP=1,3±0,6; SHR: S=19,4±2,7*, CNP=2,1±0,7#; TNF-α W: S=1,1±0,7, CNP=1,0±0,5; SHR: S=15,7±3,4*, CNP=1,5±0,9#. Values are means ± SEM. *p